0.12
-0.005(-4.17%)
Currency In GBp
Address
Maddox House
London, W1S 2PZ
United Kingdom of Great Britain and Northern Ireland
Phone
44 20 3034 2820
Website
Sector
Healthcare
Industry
Biotechnology
Employees
7
First IPO Date
May 21, 2021
| Name | Title | Pay | Year Born |
| Ms. Clarissa Ann Sowemimo-Coker | Chief Executive Officer & Executive Director | 215,669 | 1980 |
| Mr. Indraneil Mahapatra | Co-Founder & Non-Executive Director | 25,000 | 1980 |
| Mr. Paul William Smalley | Finance Director & Executive Director | 155,159 | 1973 |
| Mr. Robin Bennett | General Counsel & Company Secretary | 0 | N/A |
| Dr. Valentino Parravicini | Chief Scientific Officer | 0 | 1969 |
| Dr. Timothy Henry Corn FFPM, M.Sc. | Executive Director & Chief Medical Officer | 0 | 1951 |
Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 receptor agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.